Delcath Systems, Inc. (DCTH) - Long-Term Debt to Capital

Revenue for Delcath Systems, Inc. (DCTH) is being constrained by the slow adoption of Hepzato protocols in clinics and high development costs. Delcath Systems, Inc. (DCTH) has developed a unique local liver chemotherapy system with blood filtration that minimizes systemic harm. This historical price chart reflects the asset's dynamics, where the key metric is 0.02, and business success relies on scaling Hepzato Kit sales and controlling operating expenses.

This indicator measures the proportion of long-term credit obligations relative to equity, allowing for an assessment of the business's financial stability and debt load over a long-term horizon. The current long-term debt-to-equity ratio stands at 0.02, which is critically important for Delcath Systems, Inc. (DCTH), given the capital intensity of developing the PHP system and the stringent FDA regulatory requirements for bringing medical devices to market.